Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Elite PharmaceuticalsELTP -1.49%60 Intrinsic Value: Projected FCF is $0.16 as of Sep. 16, 2026. GuruFocus rates ELTP with a GF Score™ of 60/100 and a GF Value™ of $0.52 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 635 Drug Manufacturers companies, Elite Pharmaceuticals ranks worse than 51.18% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
The historical rank and industry rank for Elite Pharmaceuticals's Intrinsic Value: Projected FCF or its related term are showing as below:
ELTP'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 1.52 Med: 6.82 Max: 18.04
Current: 1.53
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Elite Pharmaceuticals was 18.04. The lowest was 1.52. And the median was 6.82.
ELTP's Price-to-Projected-FCF is ranked worse than 51.18% of 635
companies
in the Drug Manufacturers industry
Industry Median: 1.5
vs ELTP: 1.53
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Elite Pharmaceuticals's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
0.244995
/
0.15920750501708
=
1.54
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elite Pharmaceuticals Intrinsic Value: Projected FCF Related Terms
Elite Pharmaceuticals Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Elite Pharmaceuticals's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ELTP vs EBS, ANIK, AKBA: Intrinsic Value: Projected FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Elite Pharmaceuticals's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elite Pharmaceuticals Price-to-Projected-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Elite Pharmaceuticals's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Elite Pharmaceuticals's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of $0.16 mean?
Elite Pharmaceuticals (ELTP) has a Intrinsic Value: Projected FCF of $0.16 as of Sep. 16, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Elite Pharmaceuticals and its competitors. According to the industry distribution chart, Elite Pharmaceuticals ranks #325 out of 635 companies in the Drug Manufacturers industry, placing it in the top 51.2%.
Is Elite Pharmaceuticals' Intrinsic Value: Projected FCF too high?
Elite Pharmaceuticals' current Intrinsic Value: Projected FCF is $0.16. The Drug Manufacturers industry median Intrinsic Value: Projected FCF is 1.50. Elite Pharmaceuticals' value of $0.16 is 89.3% below this industry median. Based on the distribution chart, Elite Pharmaceuticals ranks #325 out of 635 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Elite Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Elite Pharmaceuticals' Intrinsic Value: Projected FCF compare to EBS and ANIK?
According to the Drug Manufacturers industry distribution chart, Elite Pharmaceuticals ranks #325 out of 635 companies for Intrinsic Value: Projected FCF. This places Elite Pharmaceuticals in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 1.50. Elite Pharmaceuticals' value of $0.16 is 89.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Drug Manufacturers company?
The median Intrinsic Value: Projected FCF among Drug Manufacturers companies is 1.50, based on 635 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elite Pharmaceuticals's current Intrinsic Value: Projected FCF of $0.16 is 89.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Elite Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Intrinsic Value: Projected FCF is 1.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elite Pharmaceuticals's current Intrinsic Value: Projected FCF is $0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elite Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Elite Pharmaceuticals (ELTP) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.52, compared to a current price of $0.24 — trading 52.9% below its estimated fair value. The current Intrinsic Value: Projected FCF is $0.16 and 89.3% below the Drug Manufacturers industry median of 1.50. Elite Pharmaceuticals' overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Elite Pharmaceuticals (ELTP), the current Intrinsic Value: Projected FCF is $0.16 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elite Pharmaceuticals (ELTP) Overvalued in 2026?
Based on GuruFocus' analysis, Elite Pharmaceuticals stock appears to be undervalued.
The current stock price of $0.24 is trading 52.9% below its estimated GF Value™ of $0.52.
GuruFocus considers Elite Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for ELTP:
Intrinsic Value: Projected FCF: $0.16
GF Value™: $0.52 vs. price of $0.24 (52.9% below fair value)
Industry Position: 89.3% below the Drug Manufacturers median (#325 of 635)
No single metric tells the full story. See the ELTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
60GF Score
Get the complete analysis for ELTP
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELTP has been successfully added to your 
